InMed Pharmaceuticals

(IMLFF:OTCMKTS)

R&D Biopharmaceutical Therapies

InMed Pharmaceuticals (IMLFF:OTCMKTS) is a biopharmaceutical company that specializes in developing therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary “Intelligent Cannabinoid Drug Design Platform” to identify new bioactive compounds within the cannabis plant that interact with certain genes responsible for specific diseases. These newly discovered drug candidates are developed from cannabinoids and other botanical sources significantly reduce side effects while optimizing therapeutic benefits.

R&D
Pharmacology of Cannabinoids

InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Aurora is one of 35 licensed producers across Canada and the only one located in Alberta. Boasting the second Our proprietary Cannabinoid Drug Design Platform ("CDP") allows bioinformatics tools to identify individual chemical compounds from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions.

This Platform Technology, coupled with our highly capable team, will enable the Company to discover therapies based on scientifically proven genomics and metabolomics both quickly and effectively.

Recent News

OFFICIAL STOCK INFO

Schedule a time with Momentum to discuss further

TOP
Message Us
Loading...